UCSD’s Jacobs School of Engineering. “This testing facility will hopefully lead to closer collaborations with our industry partners.
Switch™ for automobiles. The compact switch’s high operation force protects against accidental operati- on, making it suitable for car AV equipment as well as keyless entry or car navigation systems. Sample shipments will commence from April 2010. This new TACT Switch™ combines a high operation force of four Newtons with a long operating life of 200,000 cycles. A new metal contact (metallic board spring) was developed for the switch and ALPS made full use of its quality engineering and analysis technology to create the contact’s optimum configuration.
table to AMCOL shareholders of $0.20 per diluted share as compared to $0.14 per diluted share in the prior year‘s period. Net sales increased 6.4% to $175.0 million for the quarter ended March 31, 2010 from $164.4 million in the 2009 period. Foreign currency fluctuations had a favorable 3.8% impact on AMCOL‘s sales results for the quarter. As compared to the prior year‘s first quarter, operating profit increased marginally and AMCOL‘s losses from affiliates and joint ventures approximated the same
MCOL International Corporation (NYSE: ACO) reported 2010 first quarter net income attribu-
LPS ELECTRIC EUROPE (ALPS Electric, Tokyo: 6770) announced its new SKSG Series TACT
amount. AMCOL‘s interest expense was less than the prior year‘s quarter as it benefited from overall lower average interest rates as well as the significant amount of debt reduction throughout 2009. Long- term debt increased $6.0 million to $213.0 million at March 31, 2010, compared to $207.0 million at December 31, 2009. The increase was primarily due to AMCOL‘S increased working capital levels and capital expenditures. Total long-term debt, net represented 36.0% of capitalization at March 31, 2010, compared with 35.3% at December 31, 2009. Cash and cash equivalents decreased $4.3 million to $23.4 million at March 31, 2010 compared to December 31, 2009.
Inc. focused on the development of new drug thera- pies. Under the terms of the multi-year agreement, AMRI will provide fully integrated drug discovery ser- vices including assay development, screening, in vitro ADMET, computer-aided drug discovery (CADD) and medicinal chemistry.
“AMRI has a proven track record of success working with biotech companies such as Navigen,” said Mi- chael P. Trova, Ph.D., senior vice president, chemi- stry. “Our ability to execute integrated biology and chemistry services under the helm of an experienced project manager ensures best practices are applied to the delivery of high quality preclinical candidates with a strong intellectual property position to our customers. We look forward to the opportunity to work with Navigen to help advance their early drug discovery efforts.”
MRI (NASDAQ:AMRI) has initiated a research
collaboration with Navigen Pharmaceuticals,
10-04 :: April 2010